Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Ambrilia Biopharma was formed on 1st March 2006, following Procyon Biopharma's acquisition of Cellpep SA, a French, privately-held biotechnology company. The company is actively engaged in the discovery and development of innovative cancer therapeutic, screening and diagnostic products and technologies, plus therapeutics for infectious diseases. Procyon was originally incorporated as Waverly Mansion Corporation on 27th November 1986 and commenced operations in March 1989. On 13th April 1987, the corporation changed its name to Vetrogen Corporation and this was changed on 16th May 1994 to Procyon Biopharma Inc.